選択的アルドステロンブロッカーのすべて

出版社: 先端医学社
著者:
発行日: 2009-12-15
分野: 臨床医学:内科  >  内分泌/代謝
ISBN: 9784884075859
電子書籍版: 2009-12-15 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

5,060 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,530 円(税込)

商品紹介

本書では、これまでの臨床使用経験と大規模臨床試験のエビデンスを踏まえアルドステロンを実践で使用する際の方法をあらゆる角度から検証した。本書は内分泌の領域に関心をもつ医師だけでなく、日常臨床に携わる医師・研修医や学生の方々にも広く読んでいただきたい一冊。

目次

  • 選択的アルドステロンブロッカーのすべて

    ―目次―

    Part 1 選択的アルドステロンブロッカーのプロファイル
    Part 2 アルドステロンによる臓器障害を検証する
    Part 3 選択的アルドステロンブロッカーによる
         高血圧の治療戦略を検証する
    Part 4 選択的アルドステロンブロッカーによる
         イベント発症抑制効果を検証する
    Part 5 臨床からみた選択的アルドステロンブロッカーの
         今日的意義を検証する
    Part 6 選択的アルドステロンブロッカーの使い方と安全性をみる

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 / 選択的アルドステロンブロッカーのプロファイル

P.21 掲載の参考文献
1) Nicholls MG, Richards AM, Yandle TG : The renin-angiotensin system. In : Manual of Hypertension, eds by Giuseppe Mancia, Julius Stevo, John Chalmers et al, Churchill Livingstone, London, 2002, pp.77-95
2) Simpson SA, Tait JF, Wettstein A et al : Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism. Experientia 9 : 333-335, 1953
3) Conn JW : Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 : 3-17, 1955
4) Ondetti MA, Rubin B, Cushman DW : Design of specific inhibitors of angiotensin-converting enzyme : new class of orally active antihypertensive agents. Science 196 : 441-444, 1977
5) Weinstock J, Keenan RM, Samanen J et al : 1- (carboxybenzyl) imidazole-5-acrylic acids : potent and selective angiotensin II receptor antagonists. J Med Chem 34 : 1514-1517, 1991
6) Kagawa CM, Cella JA, van Arman CG : Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 126 : 1015-1016, 1957
7) de Gasparo M, Joss U, Ramjoue HP et al : Three new epoxy-spirolactone derivatives : characterization in vivo and in vitro. J Pharmacol Exp Ther 240 : 650-656, 1987
8) Paul M, Poyan Mehr A, Kreutz R : Physiology of local renin-angiotensin systems. Physiol Rev 86 : 747-803, 2006
9) 岩井將, 堀内正嗣 : レニン・アンジオテンシン系の病態生理 : 脳・認知機能. THE ARB-Angiotensin II Receptor Blocker, 堀内正嗣編, メディカルレビュー社, 東京, 2006, pp.149-155
10) Falkenstein E, Christ M, Feuring M et al : Specific nongenomic actions of aldosterone. Kidney Int 57 : 1390-1394, 2000
11) Harada E, Yoshimura M, Yasue H et al : Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 : 137-139, 2001
12) Ullian ME, Schelling JR, Linas SL : Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 20 : 67-73, 1992
13) 猿田享男 : アルドステロンの新しい作用. 成人病と生活習慣病 38 : 1331-1336, 2008
14) Pitt B, Zannad F, Remm W et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
15) Pitt B, Remme W, Zannad F et al : Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
16) Stier CT Jr : Eplerenone : a selective aldosterone blocker. Cardiovasc Drug Rev 21 : 169-184, 2003
17) Saruta T, Kageyama S, Ogihara T et al : Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension : a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens (Greenwich) 6 : 175-183, 2004
18) Staessen J, Lijnen P, Fagard R et al : Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91 : 457-465, 1981
19) Sato A, Saruta T : Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 16 (9 Pt 1) : 781-788, 2003
20) Sato A, Hayashi K, Naruse M et al : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 : 64-68, 2003
P.28 掲載の参考文献
1) 吉本貴宣, 平田結喜緒 : 内分泌高血圧の臨床概念のパラダイムシフト-副腎を中心に-ホルモンと臨床 59 : 2221-2227, 2004
2) Yoshimoto T, Hirata Y : Aldosterone as a cardiovascular risk hormone. Endcr J 54 : 359-370, 2007
3) Swedberg K, Eneroth P, Kjekshus J et al : Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality CONSENSUS Trial Study Group. Circulation 82 : 1730-1736, 1990
4) Vasan RS, Evans JC, Benjamin EJ et al : Relations of serum aldosterone to cardiac structure : gender-related differences in the Framingham Heart Study. Hypertension 43 : 957-962, 2004
5) Pitt B, Zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
6) Pitt B, Remme W, Zannad F et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
7) Pitt B, Reichek N, Willenbrock R et al : Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy : the 4E-left ventricular hypertrophy study. Circulation 108 : 1831-1838, 2003
8) Brilla CG, Pick R, Tan LB et al : Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67 : 1355-1364, 1990
9) Rajagopalan S, Duquaine D, King S et al : Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105 : 2212-2216, 2002
10) Takai S, Jin D, Muramatsu M et al : Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46 : 1135-1139, 2005
11) Funder JW : Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 217 : 263-269, 2004
12) Rocha R, Rudolph AE, Frierdich GE et al : Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 : H1802-H1810, 2002
13) Brilla CG, Weber KT, Pick R et al : Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26 : 671-677, 1992
14) Blasi ER, Rocha R, Rudolph AE et al : Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63 : 1791-1800, 2003
15) Sun Y, Zhang J, Lu L et al : Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol 161 : 1773-1781, 2002
16) Hirono Y, Yoshimoto T, Suzuki N et al : Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension : the possible role of local renin-angiotensin system. Endocrinology 148 : 1688-1696, 2007
17) Iwashima F, Yoshimoto T, Minami I et al : Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 149 : 1009-1014, 2008
18) Ahokas RA, Warrington KJ, Gerling IC et al : Aldosteronism and peripheral blood mononuclear cell activation : a neuroendocrine-immune interface. Circ Res 93 : e124-e135, 2003
19) Harada E, Yoshimura M, Yasue H et al : Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 : 137-139, 2001
20) Sugiyama T, Yoshimoto T, Tsuchiya K et al : Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 146 : 3900-3906, 2005
P.33 掲載の参考文献
1) Fuller PJ, Young MJ : Mechanisms of mineralocorticoid action. Hypertension 46 : 1227-1235, 2005
2) Boldyreff B, Wehling M : Rapid aldosterone actions : from the membrane to signaling cascades to gene transcription and physiological effects. J Steroid Biochem Mol Biol 85 : 375-381, 2003
3) Pitt B, Zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
4) Pitt B, Remme W, Zannad F et al : Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
5) Delyani JA : Mineralocorticoid receptor antagonists : the evolution of utility and pharmacology. Kidney Int 57 : 1408-1411, 2000
6) Selye H : The evolution of the stress concept. Stress and cardiovascular disease. Am J Cardiol 26 : 289-299, 1970
7) Pitt B, Reichek N, Willenbrock R et al : Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy : the 4E-left ventricular hypertrophy study. Circulation 108 : 1831-1838, 2003
8) Ezekowitz JA, McAlister FA : Aldosterone blockade and left ventricular dysfunction : a systematic review of randomized clinical trials. Eur Heart J 30 : 469-477, 2009
9) Prasad A, Quyyumi AA : Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 110 : 1507-1512, 2004
10) Bianchi S, Bigazzi R, Campese VM : Antagonists of aldosterone and proteinuria in patients with CKD : an uncontrolled pilot study. Am J Kidney Dis 46 : 45-51, 2005
11) Rossing K, Schjoedt KJ, Smidt UM et al : Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy : A randomized, double-masked, cross-over study. Diabetes Care 28 : 2106-2112, 2005
12) Rocha R, Rudolph AE, Frierdich GE et al : Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 : H1802-H1810, 2002
13) Martinez DV, Rocha R, Matsumura M et al : Cardiac damage prevention by eplerenone : comparison with low sodium diet or potassium loading. Hypertension 39 : 614-618, 2002
14) Nachowiak DA, Kekec BK, Blomme EA et al : Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71 : 503-510, 1992
15) Lombes M, Alfaidy N, Eugene E et al : Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase in the human heart. Circulation 92 : 175-182, 1995
16) Jaffe IZ, Mendelsohn ME : Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96 : 643-650, 2005
17) Yoshida M, Ma J, Tomita T et al : Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail 11 : 12-16, 2005
18) Nagata K, Obata K, Xu J, Ichihara S et al : Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47 : 656-664, 2006
19) Funder JW : Mineralocorticoid receptors and cardiovascular damage : it's not just aldosterone. Hypertension 47 : 634-635, 2006
20) Cai TQ, Wong B, Mundt SS et al : Induction of 11β-hydroxysteroid dehydrogenase type 1 but not-2 in human aortic smooth muscle cells by inflammatory stimuli. J Steroid Biochem Mol Biol 77 : 117-122, 2001
21) Takeda Y : Pathophysiological roles of vascular 11β-hydroxysteroid dehydrogenase and aldosterone. J Steroid Biochem Mol Biol 85 : 443-447, 2003
22) Tsugita M, Iwasaki Y, Nishiyama M et al : Differential regulation of 11β-hydroxysteroid dehydrogenase type-1 and -2 gene transcription by proinflammatory cytokines in vascular smooth muscle cells. Life Sci 83 : 426-432, 2008
23) Funder JW, RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93 : 121-125, 2005
24) Silvestre JS, Robert V, Heymes C et al : Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 273 : 4883-4891, 1998
25) Yamamoto N, Yasue H, Mizuno Y et al : Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 39 : 958-962, 2002
26) Yoshimura M, Nakamura S, Ito T et al : Expression of aldosterone synthase gene in failing human heart : quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 87 : 3936-3940, 2002
27) Takeda Y : Vascular synthesis of aldosterone : role in hypertension. Mol Cell Endocrinol 217 : 75-79, 2004
28) Gomez-Sanchez EP, Ahmad N, Romero DG et al : Origin of aldosterone in the rat heart. Endocrinology 145 : 4796-4802, 2004
29) Fiebeler A, Nussberger J, Shagdarsuren E et al : Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111 : 3087-3094, 2005
30) Fedorova OV, Talan MI, Agalakova NI et al : Endogenous ligand of α1sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension. Circulation 105 : 1122-1127, 2002
31) Adrogue HJ, Madias NE : Sodium and potassium in the pathogenesis of hypertension. N Engl J Med 356 : 1966-1978, 2007
32) Rossi GP, Bernini G, Desideri G et al : Renal damage in primary aldosteronism : results of the PAPY Study, Hypertension 48 : 232-238, 2006
33) Nishikawa T, Suematsu S, Saito J et al : Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol 96 : 309-316, 2005
34) Shibata S, Nagase M, Yoshida S et al : Modification of mineralocorticoid receptor function by Rac1 GTPase : implication in proteinuric kidney disease. Nat Med 14 : 1370-1376, 2008
35) Nishiyama A, Abe Y : Molecular mechanisms and therapeutic strategies of chronic renal injury : renoprotective effects of aldosterone blockade. J Pharmacol Sci 100 : 9-16, 2006

Part 2 / アルドステロンによる臓器障害を検証する

P.41 掲載の参考文献
1) Fardella CE, Mosso L, Gomez-Sanchez C et al Primary hyperaldosteronism in essential hypertensives : prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 : 1863-1867, 2000
2) Nishikawa T, Omura M : Clinical characteristics of primary aldosteronism : its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 54 Suppl 1 : 83s-85s, 2000
3) Brilla CG, Pick R, Tan LB et al : Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67 : 1355-1364, 1990
4) Takeda Y, Miyamori I, Yoneda T et al : Production of aldosterone in isolated rat blood vessels. Hypertension 25 : 170-173, 1995
5) Ye P, Kenyon CJ, MacKenzie SM et al : The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart. Endocrinology 146 : 5287-5293, 2005
6) Hayashi M, Tsutamoto T, Wada A et al : Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction : extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 38 : 1375-1382, 2001
7) Uhrenholt TR, Schjerning J, Hansen PB et al : Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 93 : 1258-1266, 2003
8) Xue C, Siragy HM : Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 46 : 584-590, 2005
9) Nishikawa T, Suematsu S, Saito J et al : Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol 96 : 309-316, 2005
10) Funder JW : RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93 : 121-125, 2005
11) Funder JW : The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 7 : 151-157, 2007
12) Nagata K, Obata K, Xu J et al : Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47 : 656-664, 2006 [Commentin : Hypertension 47 : 634-635, 2006]
13) Shibata S, Nagase M, Yoshida S et al : Modification of mineralocorticoid receptor function by Rac1 GTPase : implication in proteinuric kidney disease. Nat Med 14 : 1370-1376, 2008
14) Ullian ME, Hutchison FN, Hazen-Martin DJ et al : Angiotensin II -aldosterone interactions on protein synthesis in vascular smooth muscle cells. Am J Physiol 264 : C1525-C1531, 1993
15) Harada E, Yoshimura M, Yasue H et al : Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 : 137-139, 2001
16) Sugiyama T, Yoshimoto T, Tsuchiya K et al : Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 146 : 3900-3906, 2005
17) Michel F, Ambroisine ML, Duriez M et al : Aldosterone enhances ischemia-induced neovascularization through angiotensin II -dependent pathway. Circulation 109 : 1933-1937, 2004
18) Fan YY, Baba R, Nagai Y et al : Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats ; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens Res 29 : 169-178, 2006
19) Michea L, Delpiano AM, Hitschfeld C et al : Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 146 : 973-980, 2005
20) Haseroth K, Gerdes D, Berger S et al : Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice. Biochem Biophys Res Commun 266 : 257-261, 1999
21) Min LJ, Mogi M, Li JM et al : Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 97 : 434-442, 2005
22) Ishizawa K, Izawa Y, Ito H et al : Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 46 : 1046-1052, 2005
23) Nakamura Y, Suzuki S, Suzuki T et al : MDM2 : a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. Am J Pathol 169 : 362-371, 2006
24) Farquharson CA, Struthers AD : Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 : 594-597, 2000
25) Rajagopalan S, Duquaine D, King S et al : Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105 : 2212-2216, 2002
26) Liu SL, schmuck S, Chorazcyzewski JZ et al : Aldosterone regulates vascular reactivity : short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108 : 2400-2406, 2003
27) Nagata D, Takahashi M, Sawai K et al : Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity Hypertension 48 : 165-171, 2006
28) Nishiyama A, Yao L, Nagai Y et al : Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43 : 841-848, 2004
29) Park YM, Park MY, Suh YL et al : NAD (P) H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 313 : 812-817, 2004
30) Sun Y, Zhang J, Lu L et al : Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol 161 : 1773-1781, 2002
31) Rocha R, Funder JW : The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 970 : 89-100, 2002
32) Scatena M, Liaw L, Giachelli CM : Osteopontin : a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27 : 2302-2309, 2007
33) Irita J, Okura T, Kurata M et al : Osteopontin in rat renal fibroblasts : functional properties and transcriptional regulation by aldosterone. Hypertension 51 : 507-513, 2008
34) Vantrimpont P, Rouleau JL, Ciampi A et al : Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 19 : 1552-1563, 1998
35) Swedberg K, Eneroth P, Kjekshus J et al : Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82 : 1730-1736, 1990
36) Yamamuro M, Yoshimura M, Nakayama M et al : Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology 147 : 1314-1321, 2006
37) McKelvie RS, Yusuf S, Pericak D et al : Comparison of candesartan, enalapril, and their combination in congestive heart failure : randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100 : 1056-1064, 1999
38) Sato A, Saruta T : Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 16 : 781-788, 2003
39) Pitt B, Zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
40) Pitt B, Williams G, Remme W et al : The EPHESUS trial : eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 15 : 79-87, 2001
41) Suzuki G, Morita H, Mishima T et al : Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106 : 2967-2972, 2002
42) Joffe HV, Kwong RY, Gerhard-Herman MD et al : Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 92 : 2552-2558, 2007
43) Nishiyama A, Yao L, Nagai Y et al : Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43 : 841-848, 2004
44) Sun GP, Kohno M, Guo P et al : Involvements of Rho-kinase and TGF-β pathways in aldosterone-induced renal injury. J Am Soc Nephrol 17 : 2193-2201, 2006
45) Ishizawa K, Izawa Y, Ito H et al : Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 46 : 1046-1052, 2005
46) Nagai Y, Miyata K, Sun GP et al : Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46 : 1039-1045, 2005
47) Nishiyama A, Yao L, Fan Y et al : Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 45 : 710-716, 2005
48) Diah S, Zhang GX, Nagai Y et al : Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp Cell Res 314 : 3654-3662, 2008
49) Miyata K, Rahman M, Shokoji T et al : Aldosterone stimulates reactive oxygen specles production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16 : 2906-2912, 2005
P.48 掲載の参考文献
1) Dzau V, Braunwald E : Resolved and unresolved issues in the prevention and treatment of coronary artery disease : a workshop consensus statement. Am Heart J 121 : 1244-1263, 1991
2) Fogari R, Preti P, Zoppi A et al : Prevalence of primary aldosteronism among unselected hypertensive patients : a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 30 : 111-117, 2007
3) Douma S, Petidis K, Doumas M et al : Prevalence of primary hyperaldosteronism in resistant hypertension : a retrospective observational study. Lancet 371 : 1921-1926, 2008
4) Calhoun DA, Jones D, Textor S et al : Resistant hypertension : diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51 : 1403-1419, 2008
5) Fallo F, Veglio F, Bertello C et al : Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91 : 454-459, 2006
6) Fallo F, Federspil G, Veglio F et al : The metabolic syndrome in primary aldosteronism. Curr Hypertens Rep 9 : 106-111, 2007
7) Matrozova J, Steichen O, Amar L et al : Fasting plasma glucose and serum lipids in patients with primary aldosteronism. A Controlled Cross-Sectional Study Hypertension, 2009 (in press)
8) Guo C, Ricchiuti V, Lian BQ et al : Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-γ, and proinflammatory adipokines. Circulation 117 : 2253-2261, 2008
9) Nagase M, Matsui H, Shibata S et al : Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor : role of oxidative stress. Hypertension 50 : 877-883, 2007
10) Nagata D, Takahashi M, Sawai K et al : Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 48 : 165-171, 2006
11) Min LJ, Mogi M, Li JM et al : Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 97 : 434-442, 2005
12) Montezano AC, Callera GE, Yogi A et al : Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 28 : 1511-1518, 2008
13) Iglarz M, Touyz RM, Viel EC et al : Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. Am J Hypertens 17 : 597-603, 2004
14) Keidar S, Kaplan M, Pavlotzky E et al : Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development : a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109 : 2213-2220, 2004
15) Krug AW, Grossmann C, Schuster C et al : Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem 278 : 43060-43066, 2003
16) Grossmann C, Krug AW, Freudinger R et al : Aldosterone-induced EGFR expression : interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am J Physiol Endocrinol Metab 292 : E1790-E1800, 2007
17) Suzuki J, Iwai M, Mogi M et al : Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26 : 917-921, 2006
18) Takai S, Jin D, Muramatsu M et al : Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46 : 1135-1139, 2005
19) Pitt B, Reichek N, Willenbrock R et al : Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy : the 4E-left ventricular hypertrophy study. Circulation 108 : 1831-1838, 2003
20) Nagata K, Obata K, Xu J et al : Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47 : 656-664, 2006
21) Pitt B, Remme W Zannad F et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
22) Cleland JG, Coletta AP, Clark AL : Clinical trials update from the American College of Cardiology 2007 : ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. Eur J Heart Fail 9 : 740-745, 2007
23) Kobayashi N, Yoshida K, Nakano S et al : Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 47 : 671-679, 2006
24) Pitt B, Zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
P.55 掲載の参考文献
1) Kornel L, Rafelson ME, Hayashi T et al : Arterial receptors for adrenal steroids and transport of electrolytes in vascular smooth muslce. Clin Physiol Biochem 6 : 188-200, 1988
2) Weber KT, Sun Y, Guarda E : Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 23 : 869-877, 1994
3) Takeda Y : Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens Res 27 : 781-789, 2004
4) Takeda Y, Zhu A, Yoneda T et al : Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens 20 : 1119-1124, 2007
5) Leopold JA, Dam A, Maron BA et al : Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13 : 189-197, 2007
6) Caprio M, Mammi C, Jaffe IZ et al : The mineralocorticoid receptor in endothelial physiology and disease : novel concepts in the understanding of erectile dysfunction. Curr Pharmaceutical Design 14 : 3749-3757, 2008
7) Lemarie CA, Paradis P, Schiffrin EL : New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 86 : 673-678, 2008
8) Zhu A, Yoneda T, Demura M et al : Effect of mineralocorticoid receptor blockade on the renal renin-angiotensin-system in Dahl salt-sensitive hypertensive rats. J Hypertens 27 : 800-805, 2009
9) Pitt B, Reichek H, Willenbrock R et al : Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy : The 4E-left ventricular hypertrophy study Circulation 108 : 1831-1838, 2003
10) Oberleithner H : Is the vascular endorhelium under the control of aldosterone? Facts and hypothesis. Eur J Physiol 454 : 187-193, 2007
11) Jeong Y, Chaupin DF, Matsushita K et al : Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci USA 106 : 3782-3787, 2009
12) Schiffrin EL : Effects of aldosterone on the vasculature. Hypertension 47 : 312-318, 2006
13) Brown NJ : Aldosterone and vascular inflammation. Hypertension 51 : 161-167, 2008
14) Grossmann C, Gekle M : Nongenotropic aldosterone effects and the EGFR : interaction and biological relevance. Steroids 73 : 973-978, 2008
15) Michel F, Ambroisine ML, Duriez M et al : Aldosterone enhances ischemia-induced neovascularization through angiotensin II -dependent pathway Circulation 109 : 1933-1937, 2004
P.61 掲載の参考文献
1) Kang YM, Zhang ZH, Xue B et al : Inhibition of brain proinflammatory cytokine synthesis reduces hypothalamic excitation in rats with ischemia-induced heart failure. Am J Physiol Heaqrt Circ Physiol 295 : H223-H236, 2008
2) Yu Y, Wei SG, Zhang ZH et al : Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension 51 : 727-733, 2008
3) Huang BS, White RA, Jeng AY et al : Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 296 : R994-R1000, 2009
4) Huang BS, White RA, Ahmad M et al : Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats. Am J Physiol Regul INtegr Comp Physiol 295 : R166-R172, 2008
5) Harada E, Yoshimura M, Yasue H et al : Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 : 137-139, 2001
6) Jeffe IZ, Mendelsohn ME : Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96 : 643-650, 2005
7) Yongue BG, Roy EJ : Endogenous aldosterone and corticosterone in brain cell nuclei of adrenal-intact rats : regional distribution and effects of physiological variations in serum steroids. Brain Res 436 : 49-61, 1987
8) Janiak PC, Lewis SJ, Brody MJ : Role of central mineralocorticoid binding sites in development of hypertension. Am J Physiol 259 (5 Pt 2) : R1025-R1034, 1990
9) Gomez-Sanchez EP, Venkataraman MT, Thwaites D et al : ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 258 (4 Pt 1) : E649-E653, 1990
10) Gomez-Sanchez EP : What is the role of the central nervous system in mineralocorticoid hypertension? Am J Hypertens 4 (4 Pt 1) : 374-381, 1991
11) Yu L, Romero DG, Gomez-Sanchez CE et al : Steroidogenic enzyme gene expression in the human brain. Mol Cell Endocrinol 190 : 9-17, 2002
12) Gomez-Sanchez EP, Zhou M, Gomez-Sanchez CE : Mineralocorticoids, salt and high blood pressure. Steroids 61 : 184-188, 1996
13) Gomez-Sanchez EP, Ahmad N, Romero DG et al : Is aldosterone synthesized within the rat brain? Am J Physiol Endocrinol Metab 288 : E342-E346, 2005
14) Ye P, Kenyon CJ, MacKenzie SM et al : Regulation of aldosterone synthase gene expression in the rat adrenal gland and central nervous system by sodium and angiotensin II. Endocrinology 144 : 3321-3328, 2003
15) Huang BS, Leenen FH : Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI. Am J Physiol Heart Circ Physiol 288 : H2491-H2497, 2005
16) Morizane S, Sano M, Katayama T et al : Inadequate suppression of aldosterone biosynthesis after salt intake is a primary cause of sodieum retenstion in Dahl salt sensitive rat. Circ J 73 (Suppl 1) : 404, 2009
17) Gomez-Sanchez EP : Central hypertensive effects of aldosterone. Front Neuroendocrinol 18 : 440-462, 1997
18) Zhang ZH, Francis J, Weiss RM et al : The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 283 : H423-H433, 2002
19) Holmes MC, Yau JL, Kotelevtsev Y et al : 11β-hydroxysteroid dehydrogenases in the brain : two enzymes two roles. Ann NY Acad Sci 1007 : 357-366, 2003
20) Chander PN, Rocha R, Ranaudo J et al : Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol 14 : 1990-1997, 2003
21) Rocha R, Chander PN, Khanna K et al : Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 (1 Pt 2) : 451-458, 1998
22) Dorrance AM, Osborn HL, Grekin R et al : Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 281 : R944-R950, 2001
23) Sawathiparnich P, Kumar S, Vaughan DE et al : Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 87 : 448-452, 2002
24) Huang BS, Cheung WJ, Wang H et al : Activation of brain renin-angiotensin-aldosterone system by central sodium in Wistar rats. Am J Physiol Heart Circ Physiol 291 : H1109-H1117, 2006
25) Oyamada N, Sone M, Miyashita K et al : The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology 149 : 3764-3777, 2008
26) Iwanami J, Mogi M, Okamoto S et al : Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur J Pharmacol 566 : 153-159, 2007
27) Takeda R, Matsubara T, Miyamori I et al : Vascular complications in patients with aldosterone producing adenoma in Japan : comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 18 : 370-373, 1995
28) Muratero P, Milan A, Ann T et al : Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem 4 : 75-91, 2006
29) Gomez-Sanchez EP, Elise P : Brain mineralocorticoid receptors : orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens 13 : 191-196, 2004
P.67 掲載の参考文献
1) Fardella CE, Mosso L, Gomez-Sanchez C et al : Primary hyperaldosteronism in essential hypertensives : prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 : 1863-1867, 2000
2) Nishikawa T, Omura M : Clinical characteristics of primary aldosteronism : its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 54 (Suppl 1) : 83s, 2000
3) Nishimura T, Uzu T, Fujii T et al : Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 33 : 261-266, 1999
4) Yamamuro M, Yoshimura M, Nakayama M et al : Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology 147 : 1314-1321, 2006
5) Brilla CG, Pick R, Tan LB et al : Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67 : 1355-1364, 1990
6) Sakurabayasi-Kitada S, Kawana M et al : Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice. Atherosclerosis, 2009 (in Press)
7) Rocha R, Rudolph AE, Frierdich GE et al : Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 : H1802-H1810, 2002
8) Nagata K, Obata K, Xu J et al : Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47 : 656-664, 2006
9) Duprez DA, Bauwens FR, De Buyzere ML et al : Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 71 : 17A-20A, 1993
P.75 掲載の参考文献
1) Pitt B, Zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999
2) Pitt B, Remme W, Zannad F et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
3) Shibata S, Nagase M, Yoshida S et al : Podocyte as the target for aldosterone : roles of oxidative stress and Sgk1. Hypertension 49 : 355-364, 2007
4) Nishiyama A, Yao L, Nagai Y et al : Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43 : 841-848, 2004
5) Terada Y, Kobayashi T, Kuwana H et al : Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol 16 : 2296-2305, 2005
6) Nagai Y, Miyata K, Sun GP et al : Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46 : 1039-1045, 2005
7) Brilla CG, Weber KT : Mineralocorticoid excess, dietarysodium and myocardial fibrosis. J Lab Clin Med 120 : 893-901, 1992
8) Blasi ER, Rocha R, Rudolph AE et al : Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63 : 1791-1800, 2003
9) Nagase M, Matsui H, Shibata S et al : Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor : role of oxidative stress. Hypertension 50 : 877-883, 2007
10) Shibata S, Nagase M, Yoshida S et al : Modification of mineralocorticoid receptor function by Rac1 GTPase : implication in proteinuric kidney disease. Nat Med 14 : 1370-1376, 2008
11) Greene EL, Kren S, Hostetter T : Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98 : 1063-1068, 1996
12) Rocha R, Chander PN, Zuckerman A et al : Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33 : 232-237, 1999
13) Rocha R, Chander PN, Khanna K et al : Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 : 451-458, 1998
14) Rocha R, Stier CT, Kifor I et al : Aldosterone : a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141 : 3871-3878, 2000
15) Nagase M, Shibata S, Yoshida S et al : Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47 : 1084-1093, 2006
16) Terada Y, Kuwana H, Kobayashi T et al : Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. J Am Soc Nephrol 19 : 238-309, 2008
17) Uhrenholt TR, Schjerning J, Hansen PB et al : Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 93 : 1258-1266, 2003
18) Arima S, Kohagura K, Xu HL et al : Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14 : 2255-2263, 2003
19) Xu G, Liu A, Liu X : Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules. Nephrology 13 : 694-701, 2008
20) Leroy V, De Seigneux S, Agassiz V et al : Aldosterone activates NF-κB in the collecting duct. J Am Soc Nephrol 20 : 131-144, 2009
21) Huang W, Xu C, Kahng KW et al : Aldosterone and TGF-β1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol 294 : F1287-F1295, 2008
22) Lijnen P, Staessen J, Fagard R et al : Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 49 : 1561-1563, 1982
23) Yoneda T, Takeda Y, Usukura M et al : Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 20 : 1329-1333, 2007
24) Sato A, Hayashi K, Naruse M et al : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 : 64-68, 2003
25) Chrysostomou A, Becker G : Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345 : 925-926, 2001
26) Juurink DN, Mamdani MM, Lee DS et al : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 : 543-551, 2004

Part 3 / 選択的アルドステロンブロッカーによる高血圧の治療戦略を検証する

P.82 掲載の参考文献
1) Staessen J, Lijnen P, Fagard R et al : Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91 : 457-465, 1981
2) McKelvie RS, Yusuf S, Pericak D et al : Comparison of candesartan, enalapril, and their combination in congestive heart failure : randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100 : 1056-1064, 1999
3) Flack JM, Oparil S, Pratt JH et al : Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41 : 1148-1155, 2003
4) Weinberger MH, White WB, Ruilope LM et al : Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 150 : 426-433, 2005
5) 平山智也, 菊池健次郎ほか : 日腎誌 46 : 第47回日腎総会抄録集, 2004
6) Sato A, Saruta T : Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29 : 13-21, 2001
7) Sato A, Hayashi K, Naruse M et al : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 : 64-68, 2001
8) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009, p43
9) Calhoun DA, White WB : Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2 : 462-468, 2008
10) Nishizaka MK, Zaman MA, Calhoun DA : Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 (11 Pt 1) : 925-930, 2003
11) Sharabi Y, Adler E, Shamis A et al : Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 19 : 750-755, 2006
12) Chapman N, Dobson J, Wilson S et al : Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 : 839-845, 2007
P.86 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009
2) White WB, Duprez D, St Hillaire R et al : Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 : 1021-1026, 2003
3) Weinberger MH, White WB, Ruilope LM et al : Effect of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 150 : 426-433, 2005
4) Flack JM, Oparil S, Pratt JH et al : Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41 : 1148-1155, 2003
P.91 掲載の参考文献
1) Cushman WC, Ford CE, Cutler JA et al, for the ALLHAT Collaborative Research Group : Success and predictors of blood pressure control in diverse North American settings : The Antihypertensive and Lipid-Lowering Treatment to Prevent Attack Trial (ALLHAT). J Clin Hypertens 4 : 393-404, 2002
2) Calhoun DA, Jones D, Textor S et al : Resistant Hypertension : Diagnosis, Evaluation, and Treatment : A Scientific Committee of the Council for High Blood Pressure Research Statement From the American Heart Association Professional Education. Circulation 117 : e510-e526, 2008
3) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009
4) Black HR, Elliott WJ, Grandits G et al, for the CONVINCE Research Group : Principal results of the Controlled onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA 289 : 2073-2082, 2003
5) Dajlof B, Devereux RB, Kjeldsen SE et al, for the LIFE study group : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomized trial against atenolol. Lancet 359 : 995-1003, 2002
6) Mosso L, Carvajal C, Gonzalez A et al : Primary aldosteronism and hypertensive disease. Hypertension 42 : 161-165, 2003
7) Calhoun DA, Nishizaka MK, Zaman MA et al : High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 40 : 892-896, 2002
8) Galley BJ, Ahmad S, Xu L et al : Screening for primary aldosteronism without discontinuing hypertensive medications : the plasma aldosterone-renin ratio. Am J Kidney Dis 37 : 699-705, 2001
9) Nishizaka MK, Zaman MA, Calhoun DA : Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 : 925-930, 2003
10) Weinberger MH, Roniker B, Krause SL et al : Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15 : 709-716, 2002
11) Krum H, Nolly H, Workman D et al : Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 : 117-123, 2002
12) White WB, Duprez D, St Hillaire R et al : Effect of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 : 1021-1026, 2003
13) Calhoun DA, White WB : Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2 : 462-468, 2008
P.98 掲載の参考文献
1) 杉晴夫 : ストレスとはなんだろう, 講談社, 東京, 2008, pp.5-192
2) Kario K, Ohashi T : Increased coronary heart disease mortality after the Hanshin-Awaji earthquake among the older community on Awaji Island. Tsuna Medical Association. J Am Geriatr Soc 45 : 610-623, 1997
3) Kario K, Ohashi T : After a major earthquake, stroke death occurs more frequently than coronary heart disease death in very old subjects. J Am Geriatr Soc 46 : 537-538, 1998
4) Kario K, McEwen BS, Pickering TG : Disasters and the heart : a review of the effects of earthquake-induced stress on cardiovascular disease. Hypertens Res 26 : 355-367, 2003
5) Pace TW, Mletzko TC, Alagbe O et al : Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 63 : 1630-1633, 2006
6) Kario K, Matsuo T, Shimada K et al : Factors associated with the occurrence and magnitude of earthquake-induced increases in blood pressure. Am J Med 111 : 379-384, 2001
7) McEwen BS : Protective and damaging effects of stress mediators. N Engl J Med 338 : 171-179, 1998
8) Hamer M, Molloy GJ, Stamatakis E : Psychological distress as a risk factor for cardiovascular events : pathophysiological and behavioral mechanisms. J Am Coll Cardiol 52 : 2156-2162, 2008
9) Duncko R, Makatsori A, Fickova E et al : Altered coordination of the neuroendocrine response during psychosocial stress in subjects with high trait anxiety. Prog Neuropsychopharmacol Biol Psychiatry 30 : 1058-1066, 2006
10) Jezova D, Hlavacova N : Endocrine factors in stress and psychiatric disorders : focus on anxiety and salivary steroids. Ann NY Acad Sci 1148 : 495-503, 2008
11) Hlavacova N, Jezova D : Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav 54 : 90-97, 2008
12) Hlavacova N, Jezova D : Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. Endocr Regul 42 : 147-153, 2008
13) Gesing A, Bilang-Bleuel A, Droste SK et al Psychological stress increases hippocampal mineralocorticoid receptor levels : involvement of corticotropin-releasing hormone. J Neurosci 21 : 4822-4829, 2001
14) Young EA, Lopez JF, Murphy-Weinberg V et al : Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 60 : 24-28, 2003
15) Joels M, de Kloet ER : Mineralocorticoid and glucocorticoid receptors in the brain. Implications for ion permeability and transmitter systems. Prog Neurobiol 43 : 1-36, 1994
16) Kuo LE, Kitlinska JB, Tilan JU et al : Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13 : 803-811, 2007
17) Ingelsson E, Pencina MJ, Tofler GH et al : Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors : the Framingham Offspring Study. Circulation 116 : 984-992, 2007
18) Krug AW, Ehrhart-Bornstein M : Aldosterone and metabolic syndrome : is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 51 : 1252-1258, 2008
19) Goodfriend TL, Calhoun DA : Resistant hypertension, obesity, sleep apnea, and aldosterone : theory and therapy. Hypertension 43 : 518-524, 2004
20) Chen J, Gu D, Jaquish CE et al ; GenSalt Collaborative Research Group : Association between blood pressure responses to the cold pressor test and dietary sodium intervention in a Chinese population. Arch Intern Med 168 : 1740-1746, 2008
21) Huang BS, Wang H, Leenen FH : Chronic central infusion of aldosterone leads to sympathetic hyperreactivity and hypertension in Dahl S but not Dahl R rats. Am J Physiol Heart Circ Physiol 288 : H517-H524, 2005
22) Huang BS, White RA, Jeng AY et al : Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 296 : R994-R1000, 2009
P.108 掲載の参考文献
1) Pitt B, Zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
2) Pitt B, Remme W, Zannad F et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
3) Mizuno Y, Yoshimura M, Yasue H et al : Aldosterone production is activated in failing ventricle in humans. Circulation 103 : 72-77, 2001
4) Mizuno Y, Yasue H, Yoshimura M et al : Adrenocorticotropic hormone is produced in the ventricle of patients with essential hypertension. J Hypertens 23 : 411-416, 2005
5) Silvestre JS, Heymes C, Oubenaissa A et al : Activation of cardiac aldosterone production in rat myocardial infarction : effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99 : 2694-2701, 1999
6) Farquharson CA, Struthers AD : Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 : 594-597, 2000
7) Rocha R, Rudolph AE, Frierdich GE et al : Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 : H1802-H1810, 2002
8) Nagata K, Obata K, Xu J et al : Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47 : 656-664, 2006
9) Robert V, Silvestre JS, Charlemagne D et al : Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 26 : 971-978, 1995
10) Pitt B, Ahmed A, Love TE et al : History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension 52 : 271-278, 2008
11) Pitt B, Reichek N, Willenbrock R et al : Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. Circulation 108 : 1831-1838, 2003
P.112 掲載の参考文献
1) Keidar S, Kaplan M, Pavlotzky E et al : Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development. A possible rolefor angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109 : 2213-2220, 2004
2) Irita J, Okura T, Kurata M et al : Osteopontin in rat renal fibroblasts : functional properties and transcriptional regulation by aldosterone. Hypertension 51 : 507-513, 2008
3) O'regan A, Berman JS : Osteopontin : a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Path 81 : 373-390, 2000
4) Kurata M, Okura T, Watanabe S et al : Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci 111 : 319-324, 2006
5) Rajagopalan S, Duquaine D, King S et al : Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105 : 2212-2216, 2002
6) Takai S, Jin D, Muramatsu M et al : Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46 : 1135-1139, 2005
7) Suzuki J, Iwai M, Mogi M et al : Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vascu Biol 26 : 917-921, 2006
8) Imanishi T, Ikejima H, Tsujioka H et al : Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 51 : 734-741, 2008
9) Savoia C, Touyz RM, Amiri F et al : Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertension. Hypertension 51 : 432-439, 2008
P.119 掲載の参考文献
1) Ogihara T, Kikuchi K, Matsuoka H et al : The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2009). Hypertens Res 32 : 3-107, 2009
2) Cascella T, Palomba S, Tauchmanova L et al : Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 91 : 4395-4400, 2006
3) Bochud M, Nussberger J, Bovet P et al : Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48 : 239-245, 2006
4) Kidambi S, Kotchen JM, Grim CE et al : Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 49 : 704-711, 2007
5) Ruano M, Silvestre V, Castro R et al : Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes Surg 15 : 670-676, 2005
6) Engeli S, Bohnke J, Gorzelniak K et al : Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45 : 356-362, 2005
7) Guo C, Ricchiuti V, Lian BQ et al : Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-γ, and proinflammatory adipokines. Circulation 117 : 2253-2261, 2008
8) Nagase M, Yoshida S, Shibata S et al : Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome : possible contribution of fat-derived factors. J Am Soc Nephrol 17 : 3438-3446, 2006
9) de Paula RB, da Silva AA, Hall JE : Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 43 : 41-47, 2004
10) Goodfriend TL, Calhoun DA : Resistant hypertension, obesity, sleep apnea, and aldosterone : theory and therapy. Hypertension 43 : 518-524, 2004
11) Torpy DJ, Bornstein SR, Taylor W et al : Leptin levels are suppressed in primary aldosteronism. Horm Metab Res 31 : 533-536, 1999
12) Haluzfk M, Sindelka G, Widimsky J Jr et al : Serum leptin levels in patients with primary hyperaldosteronism before and after treatment : relationships to insulin sensitivity. J Hum Hypertens 16 : 41-45, 2002
13) Markowska A, Neri G, Hochol A et al : Effects of leptin and leptin fragments on steroid secretion and proliferative activity of regenerating rat adrenal cortex. Int J Mol Med 13 : 139-141, 2004
14) Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A et al : Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 100 : 14211-14216, 2003
15) Krug AW, Vleugels K, Schinner S et al : Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells. Int J Obes (Lond) 31 : 1605-1616, 2007
16) Schinner S, Willenberg HS, Krause D et al : Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway Int J Obes (Lond) 31 : 864-870, 2007
17) Nagase M, Matsui H, Shibata S et al : Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor : role of oxidative stress. Hypertension 50 : 877-883, 2007
18) Fallo F, Veglio F, Bertello C et al : Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91 : 454-459, 2006
19) 島本和明 : メタボリックシンドロームにおける高血圧. The Lipid 16 : 454-459, 2005
20) Wada T, Ohshima S, Fujisawa E et al : Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology 150 : 1662-1669, 2009
21) Lastra G, Whaley-Connell A, Manrique C et al : Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG (mRen2) 27 rat. Am J Physiol Endocrinol Metab 295 : E110-E116, 2008
22) Caprio M, Feve B, Claes A et al : Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. Faseb J 21 : 2185-2194, 2007
23) Kiyomoto H, Rafiq K, Mostofa M et al : Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. J Pharmacol Sci 108 : 399-405, 2008
24) 人見浩史, 西山成 : アルドステロンと臓器障害. 細胞 40 : 314-317, 2008
25) Fujita T : Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med 86 : 729-734, 2008
26) Zulian E, Sartorato P, Benedini S et al : Spironolactone in the treatment of polycystic ovary syndrome : effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 28 : 49-53, 2005
27) 佐藤敦久, 丸山達也 : 本態性高血圧患者における選択的アルドステロンブロッカー (SAB), エプレレノンの臨床効果. 第31回日本高血圧学会総会プログラム・抄録集 : 364, 2008
28) 長谷川浩一, 西山成 : 薬剤抵抗性高齢者高血圧患者に対するエプレレノンの降圧効果. 第31回日本高血圧学会総会プログラム・抄録集 : 364, 2008
29) Ohta Y, Tsuchihashi T, Arakawa K et al : Prevalence and lifestyle characteristics of hypertensive patients with metabolic syndrome followed at an outpatient clinic in fukuoka, Japan. Hypertens Res 30 : 1077-1082, 2007
30) Matsui H, Ando K, Kawarazaki H et al : Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 52 : 287-294, 2008
31) Hitomi H, Kiyomoto H, Nishiyama A et al : Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50 : 750-755, 2007
32) 海部久美子, 清元秀泰, 人見浩史ほか : 血管平滑筋細胞においてアンジオテンシンIIはインスリンシグナルを糖代謝から細胞肥大へと変化させる. 第31回日本高血圧学会総会プログラム・抄録集 : 338, 2008
P.125 掲載の参考文献
1) Oliver WJ, Cohen EL, Neel JV : Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a "no-salt" culture. Circulation 52 : 146-151, 1975
2) Vasan RS, Evans JC, Larson MG et al : Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351 : 33-41, 2004
3) Alderman MH, Madhavan S, Ooi WL et al : Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324 : 1098-1104, 1991
4) Laragh JH : Vasoconstriction-volume analysis for understanding and treating hypertension : the use of renin and aldosterone profiles. Am J Med 55 : 261-274, 1973
5) Kaplan NM : Kaplan's Clinical Hypertension 9th Ed. Lippincott Williams & Wilkins (Philadelphia), 2006, p.74
6) Brunner HR, Laragh JH, Baer L et al : Essential hypertension : renin and aldosterone, heart attack and stroke. N Engl J Med 286 : 441-449, 1972
7) Nishimura M, Uzu T, Fujii T et al : Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 33 : 261-266, 1999
8) Morimoto A, Uzu T, Fujii T et al : Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350 : 1734-1744, 1997
9) Yamamuro M, Yoshimura M, Nakayama M et al : Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology 147 : 1314-1321, 2006
10) Nagase M, Matsui H, Shibata S et al : Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor : role of oxidative stress. Hypertension 50 : 877-883, 2007
11) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009
12) Minami J, Ishimitsu T, Matsuoka H : Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens 21 : 10-13, 2008
13) Williams GH, Burgess E, Kolloch RE et al : Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93 : 990-996, 2004
P.134 掲載の参考文献
1) Nishikawa T, Omura M : Clinical characteristics of primary aldosteronism : its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Roai Hospital. Biomed Phamacother 54 (suppl 1) : 83-85, 2000
2) Omura M, Saito J, Yamaguchi K et al : Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27 : 193-202, 2004
4) Hiramatsu K, Yamada T, Yukimura Y et al : A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 141 : 1589-1593, 1981
5) Omura M, Sasano H, Saito J et al : Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism. Hypertension Res 29 : 883-889, 2006
7) Young WF Jr, Stanson AW, Thompson GB et al : Role for adrenal venous sampling in primary aldosteronism. Surgery 136 : 1227-1235, 2004
8) Mulatero P, Stowasser M, Loh KC et al : Increased diagnosis of primary aldosteronism, including surgically corerectable forms, in centers from five continents. J Clin Endocrinol Metab 89 : 1045-1050, 2004
9) Struthers AD : Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 8 : 18-22, 2002
10) Milliez P, Girerd X, Plouin PF et al : Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45 : 1243-1248, 2005
11) Catena C, Colussi G, Nadalini E et al : Cardiovascular outocomes in patients with primary aldosteronism after treatment. Arch Intern Med 168 : 80-85, 2008
12) Sechi LA, Novello M, Lapenna R et al : Long-term renal outcomes in patients with primary aldosteronism. JAMA 295 : 2638-2645, 2006
13) Karagiannis A, Tziomalos K, Papageorgiou A et al : Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 9 : 509-515, 2008

Part 4 / 選択的アルドステロンブロッカーによるイベント発症抑制効果を検証する

P.143 掲載の参考文献
1) Doi R, Masuyama T, Yamamoto K et al : Development of different phenotypes of hypertensive heart failure : systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertension 18 : 111-120, 2000
2) Ohtani T, Ohta M, Yamamoto K et al : Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure : Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 292 : R946-R954, 2007
3) Matsui H, Ando K, Kawarazaki H et al : Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 52 : 287-294, 2008
4) Masson S, Staszewsky L, Annoni G et al : Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. J Card Fail 10 : 433-441, 2004
5) Fraccarollo D, Galuppo P, Hildemann S et al : Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 42 : 1666-1673, 2003
6) Mottram PM, Haluska B, Leano R et al : Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110 : 558-565, 2004
7) Shapiro BP, Owan TE, Mohammed S et al : Mineralocorticoid signaling in transition to heart failure with normal election fraction. Hypertension 51 : 289-295, 2008
8) Savoia C, Touyz RM, Amiri F et al : Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 51 : 432-439, 2008
9) Kawaguchi M, Hay I, Fetics B et al : Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction ; Implication for systolic and diastolic reserve limitations. Circulation 107 : 714-720, 2003
10) Funder JW : The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 7 : 151-157, 2007
11) Shibata S, Nagase M, Yoshida S et al : Modification of mineralocorticoid receptor function by Rac1 GTPase : implication in proteinuric kidney disease. Nature Med 14 : 1370-1376, 2008
12) Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP et al : Conditional rnineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111 : 3025-3033, 2005
P.149 掲載の参考文献
1) Alderman MH, Madhavan S, Ooi WL et al : Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324 : 1098-1104, 1991
2) Takeda R, Matsubara T, Miyamori I et al : Vascular complications in patients with aldosterone producing adenoma in Japan : comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 18 : 370-373, 1995
3) Shigematsu Y, Hamada M, Okayama H et al : Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 29 : 723-727, 1997
4) Rossi GP, Sacchetto A, Pavan E et al : Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 95 : 1471-1478, 1997
5) Milliez P, Girerd X, Plouin PF et al : Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45 : 1243-1248, 2005
6) Nishimura M, Uzu T, Fujii T et al : Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 33 : 261-266, 1999
7) Arima S, Kohagura K, Xu HL et al : Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14 : 2255-2263, 2003
8) Ribstein J, Du Cailar G, Fesler P et al : Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 16 : 1320-1325, 2005
9) Pitt B, Zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
10) Pitt B, Remme W, Zannad F et al ; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
11) Satoh F, Abe T, Tanemoto M et al : Localization of aldosterone-producing adrenocortical adenomas : significance of adrenal venous sampling. Hypertens Res 30 : 1083-1095, 2007
P.153 掲載の参考文献
2) Sakamoto T, Yasue H, Ogawa H et al : Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol 70 : 271-276, 1992
3) Masuda T, Yasue H, Ogawa H et al : Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina. Am Heart J 124 : 314-319, 1992
4) Brown NJ, Kim KS, Chen YQ et al : Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85 : 336-344, 2000
5) Calo LA, Zaghetto F, Pagnin E et al : Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22 phox in human mononuclear leukocytes. J Clin Endocrinol Metab 89 : 1973-1976, 2004
6) Sawathiparnich P, Kumar S, Vaughan DE et al : Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 87 : 448-452, 2002
P.159 掲載の参考文献
1) Sever PS, Dahlof B, Poulter NR et al : Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol cocentrations, in the Anglo-Scandinavian Cardiac Outcome Trial Lipid-lowering arm (ASCOT-LLA) : a multicentre randomized controlled trial. Lancet 361 : 1149-1158, 2003
2) Guo C, Ricchiuti V, Lian BQ et al : Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-γ, and proinflammatory adipokines. Circulation 117 : 2253-2261, 2008
3) Farquharson CAJ, Struthers AD : Aldosterone induces acute endothelial dysfunction in vivo in humans : evidence for an aldosterone-induced vasculopathy Clin Sci (Lond) 103 : 425-431, 2002
4) Rajagopalan S, Duquine D, King S et al : Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105 : 2212-2216, 2002
5) Takai S, Muramatsu M, Kirimura K et al : Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46 : 1135-1139, 2005
6) Keidar S, Kaplan M, Pavlotzky E et al : Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development : a possible role for angiotensin-converting enzyme and the receptors for angiotensin and aldosterone. Circulation 109 : 2213-2220, 2004
7) Keidar S, Hayek T, Kaplan M et al : Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 41 : 955-963, 2003
8) Suzuki J, Iwai M, Mogi M et al : Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26 : 917-921, 2006
9) 飯利太朗編 : 別冊『医学のあゆみ』 : アルドステロン研究の新展開, 医歯薬出版, 東京, 2008
P.166 掲載の参考文献
1) Hall JE : The kidney, hypertension, and obesity. Hypertension 41 (3 Pt 2) : 625-633, 2003
2) Rahmouni K, Correia ML, Haynes WG et al : Obesity-associated hypertension : new insights into mechanisms. Hypertension 45 : 9-14, 2005
3) Goodfriend TL, Calhoun DA : Resistant hypertension, obesity sleep apnea, and aldosterone : theory and therapy. Hypertension 43 : 518-524, 2004
4) Calhoun DA, Nishizaka MK, Zaman MA et al : Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 : 892-896, 2002
5) Fallo F, Veglio F, Bertello C et al : Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91 : 454-459, 2006
6) Giacchetti G, Ronconi V, Turchi F et al : Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism : an observational study. J Hypertens 25 : 177-186, 2007
7) Tuck ML, Sowers J, Dornfeld L et al : The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304 : 930-933, 1981
8) Goodfriend TL, Kelley DE, Goodpaster BH et al : Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 7 : 355-362, 1999
9) Massiera F, Bloch-Faure M, Ceiler D et al : Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. EASEB J 15 : 2727-2729, 2001
10) Rahmouni K, Mark AL, Haynes WG et al : Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol Endocrinol Metab 286 : E891-E895, 2004
11) Goodfriend TL, Ball DL, Egan BM et al : Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43 : 358-363, 2004
12) Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A et al : Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 100 : 14211-14216, 2003
13) Silverberg DS, Oksenberg A : Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? Curr Hypertens Rep 3 : 209-215, 2001
14) Logan AG, Perlikowski SM, Mente A et al : High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 19 : 2271-2277, 2001
15) Somers VK, Dyken ME, Clary MP et al : Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96 : 1897-1904, 1995
16) Yamauchi M, Nakano H, Maekawa J et al : Oxidative stress in obstructive sleep apnea. Chest 127 : 1674-1679, 2005
17) Fletcher EC, Bao G, Li R : Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 34 : 309-314, 1999
18) Haentjens P, Van Meerhaeghe A, Moscariello A et al : The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome : evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 167 : 757-764, 2007
19) Bazzano LA, Khan Z, Reynolds K et al : Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 50 : 417-423, 2007
20) Logan AG, Tkacova R, Perlikowski SM et al : Refractory hypertension and sleep apnoea : effect of CPAP on blood pressure and baroreflex. Eur Respir J 21 : 241-247, 2003
21) Oyamada N, Sone M, Miyashita K et al : The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology 149 : 3764-3777, 2008
22) de Paula RB, da Silva AA, Hall JE : Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 43 : 41-47, 2004
23) Nagase M, Yoshida S, Shibata S et al : Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome : possible contribution of fat-derived factors. J Am Soc Nephrol 17 : 3438-3446, 2006
24) Matsui H, Ando K, Kawarazaki H et al : Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 52 : 287-294, 2008
25) Guo C, Ricchiuti V, Lian BQ et al : Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-γ, and proinflammatory adipokines. Circulation 117 : 2253-2261, 2008
P.171 掲載の参考文献
1) Pitt B, Zannad E Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999
2) Pitt B, Remme WJ, Zannad F et al : Eplerenon, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
3) Pitt B, Reichec N, Wilenbrock R et al : Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. Circulation 108 : 1831-1838, 2003
4) Campion J, Maestro B, Mata F et al : Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promonocytic cells. J Steroid Biochem Mol Biol 70 : 211-218, 1999
5) Campion J, Maestro B, Molero S et al : Aldosterone impairs insulin responsiveness in U-937 human promonocytic cells via the downregulation of its own receptor. Cell Biochem Funct 20 : 237-245, 2002
6) Mosso LM, Carvajal CA, Maiz A et al : A possible association between primary aldosteronism and a lower β-cell function. J Hypertens 25 : 2125-2130, 2007
7) Staessen J, Lijnen P, Fagard R et al : Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91 : 457-465, 1981
8) Naruse M, Tanabe A, Sato A et al : Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40 : 28-33, 2002
9) Sato A, Hayashi K, Naruse M et al : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 : 64-68, 2003
10) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009, pp.60-62
11) Epstein M : Aldosterone receptor blockade and the role of eplerenone : evolving perspectives. Nephrol Dial Transplant 18 : 1984-1992, 2003
12) Epstein M, Williams G, Weinberger M et al : Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1 : 940-951, 2006
13) Joffe HV, Kwong RY, Gerhard-Herman MD et al : Beneficial effets of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 92 : 2552-2558, 2007
14) O'Keefe JH, Abuissa H, Pitt B : Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure : results from EPHESUS. Diabetes Obes Metab 10 : 492-497, 2008

Part 5 / 臨床からみた選択的アルドステロンブロッカーの今日的意義を検証する

P.180 掲載の参考文献
1) Piit B, Zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
2) Farquharson CA, Struthers AD et al : Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 : 594-597, 2000
3) Bauersachs J, Heck M, Fraccarollo D et al : Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction : role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39 : 351-358, 2002
4) Rodriguez JA, Godoy I, Castro P et al : Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction : randomized and double-blind study. Rev Med Chile 125 : 643-652, 1997
5) Pitt B, Remme W, Zannad F et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003, Erratum in : N Engl J Med 348 : 2271, 2003
6) Pitt B, White H, Nicolau J et al : Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 : 425-431, 2005
7) Pitt B, Gheorghiade M, Zannad F et al : Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction < or=30%. Eur J Heart Fail 8 : 295-301, 2006
8) Pitt B, Reichek N, Willenbrock R et al : Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy : the 4E-left ventricular hypertrophy study. Circulation 108 : 1831-1838, 2003
9) Saruta T, Kageyama S, Ogihara T et al : Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension : a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens (Greenwich) 6 : 175-183, 2004
10) White WB, Duprez D, St Hillaire R et al : Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 : 1021-1026, 2003
11) Krum H, Nolly H, Workman D et al : Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 : 117-123, 2002
P.188 掲載の参考文献
1) Laragh JH, Baer L, Brunner HR et al : Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 52 : 633-652, 1972
2) Mueller FB, Laragh JH : Clinical evaluation and differential diagnosis of the individual hypertensive patient. Clin Chem 37 (10 Pt 2) : 1868-1879, 1991
3) Lakkis J, Lu WX, Weir MR : RAAS escape : a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 5 : 408-417, 2003
4) Pitt B : of aldosterone blockade in patients with systolic left ventricular dysfunction : implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 217 : 53-58, 2004
5) Pitt B, Zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
6) Tanabe A, Naruse M, Hara Y et al : Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. J Hypertens 22 : 1017-1023, 2004
7) Staessen J, Lijnen P, Fagard R et al : Rise of plasma aldosterone during long-term captopril treatment. N Engl J Med 304 : 1110, 1981
8) August JT, Nelson DH, Thorn GW : Response of normal subjects to large amounts of aldosterone. J Clin Invest 37 : 1549-1555, 1958
9) Naruse M, Tanabe A, Sato A et al : Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40. 28-33, 2002
10) Sato A, Saruta T : Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29 : 13-21, 2001
11) Lee AF, MacFadyen RJ, Struthers AD : Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy : a longitudinal study. Eur J Heart Fail 1 : 401-406, 1999
12) MacFadyen RJ, Lee AF, Morton JJ et al : How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82 : 57-61, 1999
13) Cicoira M, Zanolla L, Franceschini L et al : Relation of aldosterone "escape" desplte angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 89 : 403-407, 2002
14) Tang WH, Vagelos RH, Yee YG et al : Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 39 : 70-78, 2002
15) Sato A, Hayashi K, Naruse M et al : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 : 64-68, 2003
16) Schjoedt KJ, Andersen S, Rossing P et al : Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47 : 1936-1939, 2004
17) Horita Y, Taura K, Taguchi T et al : Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton) 11 : 462-466, 2006
18) McKelvie RS, Yusuf S, Pericak D et al : Comparison of candesartan, enalapril, and their combination in congestive heart failure : randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100 : 1056-1064, 1999
19) 田辺晶代, 成瀬光栄, 高木佐知子ほか : AT1拮抗薬 (ARB) の長期投与によるアルドステロン・ブレイクスルーとその病態 生理学的意義-本態性高血圧症における検討-ホルモンと臨床 52 : 41, 2004
20) Tanabe A, Naruse M, Arai K et al : Gene expression and roles of angiotensin II type 1 and type 2 receptors in human adrenals. Horm Metab Res 30 : 490-495, 1998
21) Pitt B, Remme W, Zannad F et al : Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
22) Epstein M : Aldosterone receptor blockade and the role of eplerenone : evolving Perspectives. Nephrol Dial Transplant 18 : 1984-1992, 2003
23) Pitt B : Clinical trials of angiotensin receptor blockers in heart failure : what do we know and what will we learn? Am J Hypertens 15 (1 Pt 2) : 22S-27S, 2002
24) Juurlink DN, Mamdani MM, Lee DS et al : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 : 543-551, 2004
P.199 掲載の参考文献
1) Flack JM, Oparil S, Pratt JH et al : Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41 : 1148-1155, 2003
2) Taylor AL, Ziesche S, Yancy C et al : Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 : 2049-2057, 2004
3) Wadman M : Drug targeting : is race enough? Nature 435 : 1008-1009, 2005
4) Shimkets RA, Warnock DG, Bositis CM et al : Liddle's syndrome : heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell 79 : 407-414, 1994
5) Wilson FH, Disse-Nicodeme S, Choate KA et al : Human hypertension caused by mutations in WNK kinases. Science 293 : 1107-1112, 2001
6) Litchfield WR, Dluhy RG, Lifton RP et al : Glucocorticoid-remediable aldosteronism. Compr Ther 21 : 553-558, 1995
8) Lifton RP, Gharavi AG, Geller DS : Molecular mechanisms of human hypertension. Cell 104 : 545-556, 2001
9) Guyton AC : Blood pressure control--special role of the kidneys and body fluids. Science 252 : 1813-1816, 1991
10) Hata A : Role of angiotensinogen in the genetics of essential hypertension. Life Sci 57 : 2385-2395, 1995
11) Ferrario CM, Trask AJ, Jessup JA : Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin- (1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289 : H2281-H2290, 2005
13) Walker WG, Whelton PK, Saito H et al : Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1 : 287-291, 1979
14) Fasola AF, Martz BL, Helmer OM : Renin activity during supine exercise in normotensives and hypertensives. J Appl Physiol 21 : 1709-1712, 1966
15) Gardes J, Bouhnik J, Clauser E et al : Role of angiotensinogen in blood pressure homeostasis. Hypertension 4 : 185-189, 1982
16) Inoue I, Rohrwasser A, Helin C et al : A mutation of angiotensinogen in a patient with preeclampsia leads to altered kinetics of the renin-angiotensin system. J Biol Chem 270 : 11430-11436, 1995
17) Ishigami T, Umemura S, Tamura K et al : Essential hypertension and 5'upstream core promoter region of human angiotensinogen gene. Hypertension 30 : 1325-1330, 1997
18) Ishigami T, Tamura K, Fujita T et al : Angiotensinogen gene polymorphism near transcription start site and blood pressure : role of a T-to-C transition at intron I. Hypertension 34 : 430-434, 1999
19) Inoue I, Nakajima T, Williams CS et al : A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99 : 1786-1797, 1997
20) Jeunemaitre X, Inoue I, Williams C et al : Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet 60 : 1448-1460, 1997
21) Nakajima T, Jorde LB, Ishigami T et al : Nucleotide diversity and haplotype structure of the human angiotensinogen gene in two populations. Am J Hum Genet 70 : 108-123, 2002
22) Nakajima T, Wooding S, Sakagami T et al : Natural selection and population history in the human angiotensinogen gene (AGT) : 736 complete. AGT sequences in chromosomes from around the world. Am J Hum Genet 74 : 898-916, 2004
23) White TD, Asfaw B, DeGusta D et al : Pleistocene Homo sapiens from Middle Awash, Ethiopia. Nature 423 : 742-747, 2003
24) Li JZ, Absher DM, Tang H et al : Worldwide human relationships inferred from genome-wide patterns of variation. Science 319 : 1100-1104, 2008
25) Young JH, Chang YP, Kim JD et al : Differential susceptibility to hypertension is due to selection during the out-of-Africa expansion. PLoS Genet 1 : e82, 2005
26) Rohrwasser A, Morgan T, Dillon HF et al : Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 34 : 1265-1274, 1999
27) Navar LG : The intrarenal renin-angiotensin system in hypertension. Kidney Int 65 : 1522-1532, 2004
28) Lantelme P, Rohrwasser A, Gociman B et al : Effects of dietary sodium and genetic background on angiotensinogen and Renin in mouse. Hypertension 39 : 1007-1014, 2002
29) Rohrwasser A, Ishigami T, Gociman B et al : Renin and kallikrein in connecting tubule of mouse. Kidney Int 64 : 2155-2162, 2003
30) Davisson RL, Ding Y, Stec DE et al : Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice. Physiol Genomics 1 : 3-9, 1999
31) Carson P, Ziesche S, Johnson G et al : Racial differences in response to therapy for heart failure : analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5 : 178-187, 1999
32) Exner DV, Dries DL, Domanski MJ et al : Lesser response to anglotensln-convertmg-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344 : 1351-1357, 2001
P.206 掲載の参考文献
1) Pratt JH : Mineralocorticoid receptors. Chapter A4, In : Hypertension Primer. The Essentials of High Blood Pressure. 3rd Rd, ed by Izzo JL, Black HR, Am Heart Ass, Dallas, 2003, pp.24-26
2) Weber KT, Brilla CG : Pathological hypertrophy and cardiac interstitium : fibrosis and renin-angiotensin-aldosterone system. Circulation 83 : 1849-1865, 1991
3) Struthers AD, MacDonald TM : Review of aldosterone and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61 : 663-670, 2004
4) Williams JS, Williams GH, Raji A et al : Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens 20 : 129-136, 2006
5) Rossi E, Regolisti G, Negro A et al : High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 15 : 896-902, 2002
6) Strauch B, Zelinka T, Bernhardt R et al : Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 17 : 349-352, 2003
7) Karagiannis A, Tziomalos K, Papageorgiou A et al : Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 9 : 509-515, 2008
8) Schiffrin EL : Effects of aldosterone on the vasculature. Hypertension 47 : 312-318, 2006
9) Odermatta A, Atanasovb AG : Mineralocorticoid receptors : Emerging complexity and functional diversity. Steroids 74 : 163-171, 2009
10) Farquharson CAJ, Struthers AD : Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 : 594-597, 2000
11) Funder JW : RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93 : 121-125, 2005
12) Lal A, Veinot JP, Leenen FHH : Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. Am J Hypertens 16 : 319-323, 2003
13) Nagata K, Obata K, Xu J et al : Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47 : 656-664, 2006
14) Morimoto A, Uzu T, Fujii T et al : Sodium sensitivity and cardiovascular events with essential hypertension. Lancet 350 : 1734-1737, 1997
15) INTERSALT Cooperative Research Group. INTERSALT : an international study of electrolyte excretion and blood pressure : Results for 24 hour urinary sodium and potassium excretion. Br Med J 297 : 319-328, 1998
16) Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A et al : Human adipocytes secrete mineralocorticoid releasing factors. Proc Natl Acad Sci USA 100 : 14211-14216, 2003
17) Bochud M, Nussberger J, Bovet P et al : Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48 : 239-245, 2006
18) Guder G, Bauersachs J, Frantz S et al : Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115 : 1754-1761, 2007
19) Mizuno Y, Yoshimura M, Yasue H et al : Aldosterone production is activated in failing ventricle in humans. Circulation 103 : 72-77, 2001
P.209 掲載の参考文献
1) 大久保一郎 : 臨床経済学の基礎 (9). 日本公衛誌 55 : 177-180, 2008
2) 大久保一郎 : 臨床経済学の基礎 (10) 日本公衛誌 55 : 254-255, 2008
3) Weintraub W, Zhang Z, Mahoney EM et al : Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 111 : 1106-1113, 2005
4) Croom KE Plosker GL : Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure. Pharmacoeconimics 23 : 1057-1072, 2005
5) Heidenreich PA,, Davis BR, Cutler JA et al : Cost-effective of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension : an analysis of the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Gen Intern Med 23 : 509-516, 2008
6) Lindgren P, Buxton M, Kahan T et al : Economic evaluation of ASCOT-BPLA : antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. Heart 94 : e4, 2008

Part 6 / 選択的アルドステロンブロッカーの使い方と安全性をみる

P.214 掲載の参考文献
1) Pitt B, Zannad E Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999
2) Pitt B, Remme W, Zannad F et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
3) The RALES Investigators : Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The randomized aldactone evaluation study [RALES]). Am J Cardiol 78 : 902-907, 1996
4) Juurlink DN, Mamdani MM, Lee DS et al : Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351 : 543-551, 2004
5) Tamirisa KP, Aaronson KD, Koelling TM : Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 148 : 971-978, 2004
6) Schepkens H, Vanholder R, Billiouw JM et al : Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone : an analysis of 25 cases. Am J Med 110 : 438-441, 2001
7) Krum H, Nolly H, Wbrkman D et al : Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 : 117-123, 2002
8) Johnston LC, Grieble HG : Treatment of arterial hypertensive disease with diuretics. V. Spironolactone, an aldosterone antagonist. Arch Intern Med 119 : 225-231, 1967
9) Crane MG, Harris JJ, Winsor W 3rd : Hypertension, oral oral contraceptive agents, and conjugated estrogens. Ann Intern Med 74 : 13-21, 1971
10) White WB, Carr AA, Krause S et al : Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 92 : 38-42, 2003
11) Williams GH, Burgess E, Kolloch RE et al : Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93 : 990-996, 2004
12) Hollenberg NK, Williams GH, Anderson R et al : Symptoms and the distress they cause : comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med 163 : 1543-1548, 2003
13) Saruta T, Kageyama S, Ogihara T et al : Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension : a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens (Greenwich) 6 : 175-183, 2004
14) Hunt SA, Abraham WT, Chin MH et al : 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 : e391-e479, 2009
15) Ueno H, Yoshimura M, Nakayama M et al : Clinical factors affecting serum potassium concentration in cardio-renal decompensation syndrome. Int J Cardiol, 2008 (in press)
P.222 掲載の参考文献
1) 立石智則 : 薬物動態学と薬物相互作用. ICUとCCU 32 : 1081-1087, 2008
2) ファイザー社内資料 : セララ, 新医薬品の「使用上の注意」, 2007
3) Cook CS, Berry LM, Burton E : Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica 34 : 215-228, 2004
4) 田辺晶代, 立木美香, 渡辺大輔ほか : 選択的アルドステロン拮抗薬とARB, ACEIの比較. 成人病と生活習慣病 32 : 1369-1373, 2008
5) Krum H, Nolly D, Workman D, He W et al : : Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 : 117-123, 2002
6) 日本本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009
7) 樋口俊 : 炭酸リチウム. 日本臨牀 62 : 385-387, 2004
8) Wortsman J, Sore NG : Mitotane spironolactone antagonism in Cushing's syndrome. JAMA 238 : 2527, 1977
P.226 掲載の参考文献
1) Pitt B, zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
2) Pitt B, Remme W, Zannad F et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
3) Pitt B, Reichek N, Willenbrock R et al : Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy : the 4E-left ventricular hypertrophy study. Circulation 108 : 1831-1838, 2003
4) Pitt B, Bakris G, Ruilope LM et al : Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118 : 1643-1650, 2008
5) Epstein M, Williams GH, Weinberger M et al : Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1 : 940-951, 2006
6) Joffe HV, Kwong RY, Gerhard-Herman MD et al : Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 92 : 2552-2558, 2007
7) Sato A, Saruta T, Funder JW : Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 29 : 211-216, 2006
8) 苅尾七臣 : 抗アルドステロン高血圧治療薬エプレレノン. 株式会社スズケンホームページより
9) 松岡博昭 : 高血圧とアルドステロン受容体拮抗薬. 治療学 40 : 49-52, 2006
10) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009
P.230 掲載の参考文献
1) Weinberger MH, Roniker B, Krause SL et al : Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15 : 709-716, 2002
2) Krum H, Nolly H, Workman D et al : Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 : 117-123, 2002
3) Pitt B, Reichek N, Willenbrock R et al : Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy : The 4e-left ventricular hypertrophy study. Circulation 108 : 1831-1838, 2003
4) White WB, Duprez D, St Hillaire R et al : Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 : 1021-1026, 2003
5) Pitt B, Bakris G, Ruilope LM et al : Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (ephesus). Circulation 118 : 1643-1650, 2008
6) Pitt B, Remme W, Zannad F et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003

最近チェックした商品履歴

Loading...